US Stock Details

Get in-depth insights on US stocks, including fundamentals, financials, shareholding, peer comparison, and performance. Track key metrics, price trends, and market sentiment for informed decisions. Stay ahead with expert analysis and data-driven strategies at Motilal Oswal.

Aclarion Inc

us-stock
To Invest in {{usstockname}}
us-stock
$6.69 -0.0823(-8.23%) ACON at 04 Dec 2025 04:25 PM Health Information Services
Lowest Today 6.4
Highest Today 6.59
Today’s Open 6.59
Prev. Close 7.17
52 Week High 3500.41
52 Week Low 5.55
Day’s Range: Low 6.4 High 6.59
52-Week Range: Low 5.55 High 3500.41
1 day return -
1 Week return -6.79
1 month return -12.73
3 month return -20.24
6 month return -1.93
1 year return +3555.55
3 year return -42.85
5 year return -
10 year return -

Institutional Holdings

UBS Group AG 0.30

Vanguard Institutional Extnd Mkt Idx Tr 0.29

Fidelity Extended Market Index 0.17

Spartan Total Market Index Pool G 0.05

Tower Research Capital LLC 0.01

Bank of America Corp 0.00

CLEAR STREET LLC. 0.00

State St US Extended Mkt Indx NL Cl C 0.00

Morgan Stanley - Brokerage Accounts 0.00

Market Status

Strong Buy: 1

Buy: 0

Hold: 0

Sell: 0

Strong Sell: 0

Fundamentals

Market Cap 3.58 M

PB Ratio 0.3491

PE Ratio 0.0

Enterprise Value 3.97 M

Total Assets 2.12 M

Volume 29839

Company Financials

Annual Revenue FY23:75404 0.1M, FY22:60444 0.1M, FY21:60292 0.1M, FY20:48652 0.0M, FY19:26897 0.0M

Annual Profit FY23:-162995 -0.2M, FY22:-4854 -0.0M, FY21:-8883 -0.0M, FY20:-17593 -0.0M, FY19:-36283 -0.0M

Annual Net worth FY23:-4911374 -4.9M, FY22:-9111768 -9.1M, FY21:-3534595 -3.5M, FY20:-4790376 -4.8M, FY19:-4024093 -4.0M

Quarterly Revenue Q3/2025:18942 0.0M, Q2/2025:19319 0.0M, Q1/2025:18991 0.0M, Q3/2024:14407 0.0M, Q2/2024:10971 0.0M

Quarterly Profit Q3/2025:4386 0.0M, Q2/2025:5140 0.0M, Q1/2025:-4488 -0.0M, Q3/2024:-6925 -0.0M, Q2/2024:-12323 -0.0M

Quarterly Net worth Q3/2025:-1706294 -1.7M, Q2/2025:-1600757 -1.6M, Q1/2025:-2037436 -2.0M, Q3/2024:-1366176 -1.4M, Q2/2024:-1238077 -1.2M

Fund house & investment objective

Company Information Aclarion, Inc. operates as a healthcare technology company in the United States. The company uses magnetic resonance spectroscopy (MRS) and proprietary biomarkers to optimize clinical treatments. It develops NOCISCAN, which uses MRS capabilities to non-invasively analyze the chemical makeup of intervertebral discs in the spine. The company also provides NOCISCAN MRS Exam Protocol, a custom software protocol for using commercially available MRS pulse sequences in scanning intervertebral discs which extends the time of a standard lumbar MRI exam; and data transfer products, including AMBRA Healthcare, an imaging data transfer platform and NOCIWEB, a custom developed web-interface. In addition, it offers The NOCISCAN Post-Processor Suite comprising NOCICALC, a Class I medical device that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra, and performs various degenerative pain biomarker calculations from those spectra, for each disc examined; and NOCIGRAM, which further processes the NOCICALC results into individual NOCISCORES, on a 0-10 scale, that represent the different relative levels of degenerative pain biomarkers the various discs examined in the patient. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was incorporated in 2008 and is based in Broomfield, Colorado.

Organisation Health Information Services

Employees 5

Industry Health Information Services

CEO Mr. Brent Ness

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right